Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 1/20 | 0.54 |
| ▸ | ACACB | O00763 | 1/20 | 0.52 |
| ▸ | ACACA | Q13085 | 1/20 | 0.52 |
| ▸ | PPARA | Q07869 | 8/20 | 0.41 |
| ▸ | TBXAS1 | P24557 | 4/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | TTR | P02766 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.39 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.39 |
| ▸ | GUCY1A1 | Q02108 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5795040 | 0.93 | ACLY (0.57) | ACLYACACBACACAPPARATBXAS1 | |
| SCHEMBL7161723 | 0.91 | ACLY (0.61) | ACLYACACBACACAPPARATBXAS1 | |
| SCHEMBL4035472 | 0.91 | ACLY (0.61) | ACLYACACBACACAPPARATBXAS1 | |
| SCHEMBL27754242 | 0.91 | ACLY (0.61) | ACLYACACBACACAPPARATBXAS1 | |
| SCHEMBL1558118 | 0.84 | — | — | |
| SCHEMBL7222208 | 0.84 | ACLY (0.70) | ACLYACACBACACAPPARATBXAS1 | |
| SCHEMBL2784372 | 0.84 | ACLY (0.62) | ACLYACACBACACAPPARATBXAS1 | |
| SCHEMBL9664505 | 0.82 | ACLY (0.56) | ACLYACACBACACAPPARATBXAS1 | |
| SCHEMBL2977206 | 0.82 | ACLY (0.47) | ACLYACACBACACAPPARATSHR | |
| SCHEMBL5528331 | 0.81 | ACLY (0.74) | ACLYACACBACACAPPARATBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2079722-B1 | SUBSTITUTED 3-PHENYL-1-(PHENYLTHIENYL)PROPAN-1-ONE AND 3-PHENYL-1-(PHENYLFURANYL)PROPAN-1-ONE DERIVATIVES, AND PREPARATION AND USE OF SAME | GENFIT (FR) | 2015-06-17 | — | — | EP | disclosed |
| EP-2079722-A2 | SUBSTITUTED 3-PHENYL-1-(PHENYLTHIENYL)PROPAN-1-ONE AND 3-PHENYL-1-(PHENYLFURANYL)PROPAN-1-ONE DERIVATIVES, AND PREPARATION AND USE OF SAME | Genfit (FR) | 2009-07-22 | — | — | EP | disclosed |
| EP-2049107-A2 | SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATION AND USES | Genfit (FR) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008087366-A2 | SUBSTITUTED 3-PHENYL-1-(PHENYLTHIENYL)PROPAN-1-ONE AND 3-PHENYL-1-(PHENYLFURANYL)PROPAN-1-ONE DERIVATIVES, AND PREPARATION AND USE OF SAME | GENFIT (FR) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008087367-A2 | SUBSTITUTED (PHENYLTHIAZOLYL)-PHENYL-PROPAN-1-ONE AND (PHENYLOXAZODYL)-PHENYL-PROPAN-1-ONE DERIVATIVES, PREPARATIONS AND USES OF SAME | GENFIT (FR) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008012470-A2 | SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATION AND USES | GENFIT (FR) | 2008-01-31 | — | — | WO | disclosed |
| WO-2007118964-A1 | SUBSTITUTED N-(PHENETHYL)BENZAMIDE DERIVATIVES, PREPARATION AND USES THEREOF | GENFIT (FR) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007118963-A2 | SUBSTITUTED N-(PHENETHYL)BENZAMIDE DERIVATIVES, PREPARATION AND USES THEREOF | GENFIT (FR) | 2007-10-25 | — | — | WO | disclosed |
| WO-2006035157-A2 | SUBSTITUTED N-(BENZYL)PHENYLACETAMIDE DERIVATIVE COMPOUNDS, PREPARATION METHOD THEREOF AND USES OF SAME AS PPAR LIGANDS IN THE TREATMENT OF LIPID AND/OR GLUCIDIC DISORDERS | GENFIT (FR) | 2006-04-06 | — | — | WO | disclosed |
| US-20050119489-A1 | 4-Sulfide/sulfoxide/sulfonyl-1h-pyrazolyl derivative compounds, for use in diseases associated with the 5-ht2c receptor | BAYER HEALTHCARE AG (DE) | 2005-06-02 | — | — | US | disclosed |
| EP-1465872-A1 | 4-SULFIDE/SULFOXIDE/SULFONYL-1H-PYRAZOLYL DERIVATIVE COMPOUNDS, FOR USE IN DISEASES ASSOCIATED WITH THE 5-HT2C RECEPTOR | Bayer Pharmaceuticals Corporation (US) | 2004-10-13 | — | — | EP | disclosed |
| WO-2003057674-A1 | 4-SULFIDE / SULFOXIDE / SULFONYL-1H-PYRAZOLYL DERIVATIVE COMPOUNDS, FOR USE IN DISEASES ASSOCIATED WITH THE 5-HT2C RECEPTOR | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119489-A1 | 4-Sulfide/sulfoxide/sulfonyl-1h-pyrazolyl derivative compounds, for use in diseases associated with the 5-ht2c receptor | HTR2C, HTR2A, HTR2B | ACLY 3277/4885ACACB 3279/4885ACACA 3670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.